



SERES
THERAPEUTICS™

Seres Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference

January 6, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres, will present a company overview at the 34th annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, Jan. 13, at 3 p.m. PT at the Westin St. Francis Hotel.

Live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website at www.serestherapeutics.com. A replay of the presentation will be available approximately one hour after the event and will be archived on the website for 14 days.

About Seres Therapeutics

Seres Therapeutics Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160106005214/en/>

Source: Seres Therapeutics Inc.

IR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com

or

PR Contact:

Ten Bridge Communications
Dan Quinn, 781-475-7974
Dan@tenbridgecommunications.com